摘要
目的:评价低剂量柳氮磺吡啶(SASP)联合金双歧治疗溃疡性结肠炎的疗效和安全性。方法:低剂量SASP(1g/次,3次/d)联合金双歧治疗61例轻中型溃疡性结肠炎患者。结果:55例患者完成了整个疗程,其临床、结肠镜和病理组织学缓解率分别为72.7%,21.8%和16.4%。61例溃疡性结肠炎患者临床显效率为63.9%,总有效率为82.0%。共有10例(16.4%)发生了1次及以上的不良反应。结论:低剂量SASP联合金双歧治疗轻中型溃疡性结肠炎的近期疗效和安全性较好,尤以临床症状改善显著。
Objective：To investigate the effective and safety of low dose sulfasalazine （SASP） plus golden bifido in the treatment of patients with mild and moderate ulcerative colitis（UC）.Methods：61 patients were treated with SASP（1g,id） plus golden bifido.Results：After 55 patients were treated for 6 weeks,the clinical,colonoscopic and histological remission were 72.7%, 21.8% and 16.4%,respectively.The curative rates and the effective rates were 63.9% and 82.0%,respectively.Among the 61 patients,10 of them （16.4%） had adverse reactions.Conclusion：Low dose SASP plus golden bifido can be an effective and safe medicine in treatment of patients with mild and moderate UC,and more than half of the patients showed clinical remission.
出处
《中国当代医药》
2009年第13期32-33,共2页
China Modern Medicine
关键词
药效学
不良反应
柳氮磺吡啶
金双歧
溃疡性结肠炎
Pharmacodynamics
Adverse reactions
Sulfasalazine（SASP）
Golden bifido
Ulcerative colitis （UC）
